Pfizer’s New Vaccine Protects Newborns from Respiratory Syncytial Virus (RSV)
In a breakthrough development, pregnant individuals can now receive a vaccine that safeguards their newborns against respiratory syncytial virus (RSV). Manufactured by Pfizer, the vaccine known as Abrysvo sends protective antibodies to the developing fetus through the placenta.
The United States Food and Drug Administration (FDA) approved Abrysvo in August, and now the Centers for Disease Control and Prevention (CDC) has recommended its use. Clinical trials have demonstrated that this vaccine significantly reduces the risk of lung infections and severe cases of RSV in newborns.
To ensure utmost efficacy, the CDC recommends administering the vaccine during and in preparation for RSV season, which typically occurs from late fall to early spring. For those giving birth during this season, the vaccine should ideally be given between weeks 32 and 36 of pregnancy.
Moreover, the CDC asserts that discussions with healthcare professionals should include the topic of RSV protection, which may include post-birth immunization options for infants. By means of immunization, infants receive drugs containing laboratory-made antibodies that shield them against RSV.
It is worth noting that although there is currently no RSV vaccine approved for babies, there are antibody drugs readily available. In most cases, the CDC suggests that infants will likely only need protection from either the maternal RSV vaccine or via infant immunization.
This groundbreaking development provides hope for expectant parents who have long sought ways to protect their babies from RSV. With Abrysvo’s approval and CDC recommendation, pregnant individuals can now safeguard their newborns from this dangerous virus, offering peace of mind during a vulnerable time.
